Literature DB >> 12756506

Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma.

Ekaterina S Jordanova1, Katja Philippo, Marius J Giphart, Ed Schuuring, Philip M Kluin.   

Abstract

Loss of expression of human leukocyte antigen (HLA) class II molecules on tumor cells affects the onset and modulation of the immune response through lack of activation of CD4+ T lymphocytes. Previously, we showed that the frequent loss of expression of HLA class II in diffuse large B-cell lymphoma (DLBCL) of the testis and the central nervous system (CNS) is mainly due to homozygous deletions in the HLA region on chromosome band 6p21.3. A minority of cases showed hemizygous deletions or mitotic recombination, implying that mutation of the remaining copy of the class II genes might be involved. Here, we studied three DLBCLs with loss of HLA-DQ expression for mutations in the DQB1 and DQA1 genes and three tumors with loss of HLA-DR expression for mutations in the DRB1 and DRA genes. In one case, a point mutation in exon 2 of the DQB1 gene, leading to the formation of a stop codon, was detected at position 47. In a second case, a stop codon was found at position 11 due to a deletion of 19 bp in exon 1 of the DRA gene. No mutations were found in the promoter sequences of the DRA, DQA1 and DQB1 genes. We conclude that both homozygous deletions and hemizygous deletions or mitotic recombination with mutations of the remaining allele may lead to loss of expression of the HLA class II genes, which is comparable to the mechanisms affecting HLA class I expression in solid cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12756506     DOI: 10.1007/s00251-003-0563-z

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  42 in total

Review 1.  Genetic control of MHC class II expression.

Authors:  Jenny Pan-Yun Ting; John Trowsdale
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

Review 2.  MHC antigens and tumor escape from immune surveillance.

Authors:  F Garrido; I Algarra
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

3.  Nomenclature for factors of the HLA system, 2002.

Authors:  Steven G E Marsh; Ekkehard D Albert; Walter F Bodmer; Ronald E Bontrop; Bo Dupont; Henry A Erlich; Daniel E Geraghty; John A Hansen; Bernard Mach; Wolfgang R Mayr; Peter Parham; Effie W Petersdorf; Takehiko Sasazuki; Geziena M Th Schreuder; Jack L Strominger; Arne Svejgaard; Paul I Terasaki
Journal:  Eur J Immunogenet       Date:  2002-12

4.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Authors:  S M Ansell; M Stenson; T M Habermann; D F Jelinek; T E Witzig
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

5.  Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.

Authors:  M Hishii; J T Kurnick; T Ramirez-Montagut; F Pandolfi
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

6.  CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro.

Authors:  M S Brady; F Lee; H Petrie; D D Eckels; J S Lee
Journal:  Cancer Immunol Immunother       Date:  2000-02       Impact factor: 6.968

7.  Multiple mechanisms underlie HLA dysregulation in cervical cancer.

Authors:  C S Brady; J S Bartholomew; D J Burt; M F Duggan-Keen; S Glenville; N Telford; A M Little; J A Davidson; P Jimenez; F Ruiz-Cabello; F Garrido; P L Stern
Journal:  Tissue Antigens       Date:  2000-05

8.  Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.

Authors:  Magda Dziembowska; Marie-Claude Fondaneche; Jocelyn Vedrenne; Giovanna Barbieri; Wojciech Wiszniewski; Capucine Picard; Andrew J Cant; Viktor Steimle; Dominique Charron; Catherine Alca-Loridan; Alain Fischer; Barbara Lisowska-Grospierre
Journal:  Immunogenetics       Date:  2002-01-29       Impact factor: 2.846

9.  Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes.

Authors:  M K Newell; J VanderWall; K S Beard; J H Freed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

10.  Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.

Authors:  L A Koopman; W E Corver; A R van der Slik; M J Giphart; G J Fleuren
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

View more
  9 in total

1.  The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.

Authors:  I Vater; M Montesinos-Rongen; M Schlesner; A Haake; F Purschke; R Sprute; N Mettenmeyer; I Nazzal; I Nagel; J Gutwein; J Richter; I Buchhalter; R B Russell; O D Wiestler; R Eils; M Deckert; R Siebert
Journal:  Leukemia       Date:  2014-09-05       Impact factor: 11.528

2.  HLA-DRB1 and HLA-DQB1 methylation changes promote the occurrence and progression of Kazakh ESCC.

Authors:  Jian Ming Hu; Ling Li; Yun Zhao Chen; Chunxia Liu; Xiaobin Cui; Liang Yin; Lan Yang; Hong Zou; Lijuan Pang; Jin Zhao; Yan Qi; Yuwen Cao; Jinfang Jiang; Weihua Liang; Feng Li
Journal:  Epigenetics       Date:  2014-10       Impact factor: 4.528

3.  Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor.

Authors:  Fan Fei; Liang Rong; Nan Jiang; Alan S Wayne; Jianming Xie
Journal:  Mol Ther       Date:  2021-11-18       Impact factor: 11.454

4.  Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.

Authors:  Peng Song; Wenbin Li; Xiaoxuan Wu; Zhirong Qian; Jianming Ying; Shugeng Gao; Jie He
Journal:  Cancer Immunol Immunother       Date:  2022-02-13       Impact factor: 6.630

5.  Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer.

Authors:  Jiasheng Xu; Han Nie; Jiarui He; Xinlu Wang; Kaili Liao; Luxia Tu; Zhenfang Xiong
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

6.  Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma.

Authors:  Florin M Selaru; Suna Wang; Jing Yin; Karsten Schulmann; Yan Xu; Yuriko Mori; Alexandru V Olaru; Fumiaki Sato; James P Hamilton; John M Abraham; Paul Schneider; Bruce D Greenwald; Jan Brabender; Stephen J Meltzer
Journal:  Bioinform Biol Insights       Date:  2007

7.  HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients.

Authors:  Geok Wee Tan; Peijia Jiang; Ilja M Nolte; Kushi Kushekhar; Rianne N Veenstra; Bouke G Hepkema; Ruth F Jarrett; Anke van den Berg; Arjan Diepstra
Journal:  Cancers (Basel)       Date:  2021-11-20       Impact factor: 6.639

8.  Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma.

Authors:  Gerd Meyer Zu Hörste; Oliver M Grauer; Michael Heming; Svea Haessner; Jolien Wolbert; I-Na Lu; Xiaolin Li; Benjamin Brokinkel; Michael Müther; Markus Holling; Walter Stummer; Christian Thomas; Andreas Schulte-Mecklenbeck; Flavia de Faria; Marlon Stoeckius; Stephan Hailfinger; Georg Lenz; Kornelius Kerl; Heinz Wiendl
Journal:  Genome Med       Date:  2022-09-24       Impact factor: 15.266

9.  Variations in the MHC region confer risk to esophageal squamous cell carcinoma on the subjects from high-incidence area in northern China.

Authors:  Fang-Fang Shen; Wen-Bin Yue; Fu-You Zhou; Ying Pan; Xue-Ke Zhao; Yan Jin; Xin Song; Bei Li; Xue-Na Han; Sa Tang; Yan Li; Guo Yuan; Li-Sha Chen; Ya-Li Liu; Yan-Long Hu; Xiu-Min Li; Jing-Li Ren; Li-Dong Wang
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.